Anjali Mishra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/607504/publications.pdf

Version: 2024-02-01

26 papers	538 citations	759055 12 h-index	677027 22 g-index
26 all docs	26 docs citations	26 times ranked	1207 citing authors

#	Article	IF	Citations
1	Cyclophosphamide Induces Durable Molecular and Clinical Responses in Patients with Relapsed T-LGL Leukemia. Blood Advances, 2022, , .	2.5	4
2	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Blood Cancer Discovery, 2022, 3, 154-169.	2.6	8
3	Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia. Frontiers in Oncology, 2022, 12, 849917.	1.3	8
4	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. Frontiers in Oncology, 2022, 12, 858426.	1.3	0
5	Clinical outcomes in Tâ€cell large granular lymphocytic leukaemia: prognostic factors and treatment response. British Journal of Haematology, 2021, 192, 484-493.	1.2	6
6	Differential Integrin Adhesome Expression Defines Human NK Cell Residency and Developmental Stage. Journal of Immunology, 2021, 207, 950-965.	0.4	9
7	Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. Blood, 2021, 138, 2449-2449.	0.6	0
8	MicroRNAs in Cutaneous T-Cell Lymphoma: TheÂFuture of Therapy. Journal of Investigative Dermatology, 2019, 139, 528-534.	0.3	18
9	Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?. Haematologica, 2019, 104, 864-867.	1.7	2
10	Development and Significance of Mouse Models in Lymphoma Research. Current Hematologic Malignancy Reports, 2019, 14, 119-126.	1.2	2
11	The EZ-riding NK/T-cell lymphoma. Blood, 2019, 134, 1999-2000.	0.6	1
12	Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). Cancer Treatment and Research, 2019, 176, 83-98.	0.2	25
13	Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and SÃ©zary syndrome (SS). Chinese Clinical Oncology, 2019, 8, 11-11.	0.4	18
14	Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine. Blood, 2019, 134, 3776-3776.	0.6	2
15	The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages. Blood, 2018, 132, 2567-2567.	0.6	0
16	Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert Review of Hematology, 2017, 10, 111-121.	1.0	13
17	Frequency and clinical correlates of elevated plasma Epsteinâ€Barr virus DNA at diagnosis in peripheral Tâ€cell lymphomas. International Journal of Cancer, 2017, 140, 1899-1906.	2.3	15
18	MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from SÃ¨zary syndrome patients. Leukemia Research, 2017, 52, 58-66.	0.4	21

#	Article	IF	Citations
19	Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Frontiers in Oncology, 2017, 7, 22.	1.3	71
20	Frequency, cell lineage, and clinical correlates of lymphopenia in untreated T-cell lymphomas (TCL).. Journal of Clinical Oncology, 2017, 35, e19023-e19023.	0.8	0
21	Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discovery Medicine, 2017, 23, 189-199.	0.5	14
22	SÃ©zary Syndrome: Clinical and Biological Aspects. Current Hematologic Malignancy Reports, 2016, 11, 468-479.	1.2	17
23	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S181-S190.e4.	0.2	7
24	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	7.7	79
25	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3 , GATA6 , and TWIST1 in the Sezary Syndrome. Journal of Investigative Dermatology, 2015, 135, 2084-2092.	0.3	32
26	Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer. Clinical Cancer Research, 2014, 20, 2044-2050.	3.2	166